Objective: The study investigates the efficacy of advanced antibiotic compounds against Pseudomonas aeruginosa PAO1, focusing on Antibiotic B, an enhanced derivative of Ceftriaxone, and a novel adjuvant, Influximax, which augments its antibacterial activity.
Methods: The research employs fluorescence quantification to measure the intracellular uptake of antibiotics and assesses the effect of adjuvant combinations on enhancing drug resistance combat.
Results: Our findings reveal a diminished potential for resistance emergence with Antibiotic B, particularly when used in combination with Influximax. Both compounds demonstrated a significant increase in intracellular accumulation and penetration rates, offering promising avenues to effectively combat microbial resistance.
Conclusion: Optimizing antibiotic delivery into bacterial cells and leveraging synergistic adjuvant combinations can significantly enhance the effectiveness of drug resistant management strategies. This approach not only improves therapeutic outcomes but, also prolongs the efficacy of existing antimicrobial agents against resistant strains of Pseudomonas aeruginosa.
Keywords: Pseudomonas aeruginosa PAO1, Antibiotic Resistance, Next-Generation Antibiotics, Adjuvant Synergy, Intracellular Accumulation, Penetration Rates